Median Technologies

Corporate Update

October 2022

ALMDT
EURONEXT
GROWTH

European **Rising** Tech
LABEL

www.mediantechnologies.com

Disclaimer

- The information provided in this presentation pertaining to Median Technologies SA . ("Median" or the "Company"), its business assets, strategy and operations is for general informational purposes only and is not a formal offer to sell or a solicitation of an offer to buy any securities, options, futures, or other derivatives related to securities in any jurisdiction and its content is not prescribed by securities laws. Information contained in this presentation should not be relied upon as advice to buy or sell or hold such securities or as an offer to sell such securities. This presentation does not take into account nor does it provide any tax, legal or investment advice or opinion regarding the specific investment objectives or financial situation of any person. While the information in this presentation is believed to be accurate and reliable, Median and its agents, advisors, directors, officers, employees and shareholders make no representation or warranties, expressed or implied, as to the accuracy of such information and Median expressly disclaims any and all liability that may be based on such information or errors or omissions thereof. Median reserves the right to amend or replace the information contained herein, in part or entirely, at any time, and undertakes no obligation to provide the recipient with access to the amended information or to notify the recipient thereof.

- Neither Median nor any of Median's representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this presentation by you or any of your representatives or for omissions from the information in this presentation. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made by, third parties in respect of the matters discussed in this presentation.

- This presentation is intended only for persons who (i) have professional experience in matters relating to investments within the meaning of "investment professionals" as defined, (ii) to whom an invitation or inducement to engage in investment activity in connection with the issuance or sale of securities may be lawfully communicated to or caused to be communicated to (all such persons together being referred to as "Qualified Persons"). This presentation is intended for Qualified Persons only and cannot be given to persons who are not Qualified Persons. Any investment or investment activity to which this presentation refers is permitted for Qualified Persons only and will be denied to any other person.

- Certain information in this presentation and oral statements made in any meeting are forward-looking and relate to Median and its anticipated financial position, business strategy, events and courses of action. Words or phrases such as "anticipate," "objective," "may," "will," "might," "should," "could," "can," "intend," "expect," "believe," "estimate," "predict," "potential," "plan," "is designed to" or similar expressions suggest future outcomes. Forward-looking statements and financial projections include, among other things, statements about: our expectations regarding our expenses, sales and operations; our future customer concentration; our anticipated cash needs, our estimates regarding our capital requirements, our need for additional financing; our ability to anticipate the future needs of our customers; our plans for future products and enhancements of existing product or services; our future growth strategy and growth rate; our future intellectual property; and our anticipated trends and challenges in the markets in which we operate. Forward-looking statements and financial projections are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements and financial projections. Although we believe that the expectations reflected in the forward-looking statements and financial projections are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, level of activity, performance or achievements and there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking statements and financial projections.

- By their nature, forward-looking statements and financial projections involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward-looking information will not occur, which may cause the Company's actual performance and financial results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements and financial projections. Important factors that could cause actual results to differ materially from expectations include, but are not limited to: business, economic and capital market conditions; the heavily regulated industry in which the Company carries on business; current or future laws or regulations and new interpretations of existing laws or regulations; legal and regulatory requirements; market conditions and the demand and pricing for our products; our relationships with our customers, developers and business partners; our ability to successfully define, design and release new products in a timely manner that meet our customers' needs; our ability to attract, retain and motivate qualified personnel; competition in our industry; competition; technology failures; failure of counterparties to perform their contractual obligations; systems, networks, telecommunications or service disruptions or failures or cyber-attack; ability to obtain additional financing on reasonable terms or at all; our ability to manage risks inherent in foreign operations; litigation costs and outcomes; our ability to successfully maintain and enforce our intellectual property rights and defend third party claims of infringement of their intellectual property rights; our ability to manage foreign exchange risk and working capital; and our ability to manage our growth. Readers are cautioned that this list of factors should not be construed as exhaustive.

- The forward-looking statements and financial projections contained in this presentation are expressly qualified by this cautionary statement. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Readers are cautioned not to place undue reliance on forward-looking statements or financial projections. Prospective investors should not construe the contents of this presentation as legal, tax, investment or other advice. All prospective investors should make their own inquiries and consult their own advisors as to legal, tax, investment, and related matters concerning an investment in the securities of the Company.

Innovation Is in Our DNA

"Many diseases, including cancer, do not kill if diagnosed early"

We help conquer cancer and other diseases through routine AI-based imaging tests and imaging services for drug development

Our Growth: Powered by proprietary technology, strong KOL connections, and medical, scientific, technology partnerships

Our People: As of Sep 2022, 230+ employees worldwide (EU, US & China)

Our locations: HQ in France with subsidiaries in the US and in China

Our Products & Services:
- **iCRO**: imaging services for oncology trials
- **iBiopsy®**: imaging platform for AI-based routine diagnostic solutions

Example of clinical partners

ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS

UC San Diego

AI-Powered Imaging and Data-Driven Approach Are Redefining the Entire Patient Journey

Oncology Clinical Trials

Biomarker Discovery

**Patient Care:**
Early Diagnosis & Disease Monitoring

iCRO

Bringing more data insights to biopharmaceutical companies

iBiopsy®

Imaging Lab Services

AI & Data Mining Technologies

- Stage shift of biopharmaceutical companies towards early-stage cancers
- Better understanding of drugs mechanisms of action

Company View

Yan Liu, MD, MSc, PhD
Chief Medical Officer

- Board-certified radiologist
- Biomarker expert with more than 15 years of clinical research experience
- Former head of translational research, radiotherapy, and imaging department at EORTC

Fredrik Brag
Chief Executive Officer and Founder

- Co-founded the company in 2002, bringing years of technology company expertise gained in business development, fundraising, and IPOs

- Previously served as board member and Senior Executive VP of Health Center/ Focus Imaging

Corporate Support
Jean-Christophe Montigny
Chief Financial Officer

iCRO Business Unit
Nicolas Dano
Chief Operating Officer

iBiopsy® Business Unit
Thomas Bonnefont
Chief Operating and Commercial Officer

Board of Directors

Bringing significant industry, medical, financial and strategic expertise to the company

Oran Muduroglu
Chairman

Fredrik Brag
Director

Kapil Dhingra
Director

Oern Stuge
Director

Tim Haines
Director

Strong Business Momentum

*As of September 30, 2022*

median

Q3 2022 revenue at €6M

- Up 13% compared with Q3 2021
- Total revenue on Sep 30 2022: €18.7M, up 21% vs YAGO

Order backlog at €62.5M

- +15% compared to backlog at Sep. 30, 2021 (€54.1 million)

Cash and cash equivalents at €25.9M

Q3 revenue 2019-2022 (m€)

Q3 2019	Q3 2020	Q3 2021	Q3 2022
2.3	3.5	5.3	6

Q3 Order backlog 2019-2022 (m€)

Q3 2019	Q3 2020	Q3 2021	Q3 2022
35.9	50.7	54.1	62.5

iBiopsy®
Addressing the unmet medical need

"Many diseases do not kill if diagnosed at their earliest stage"

We are developing the next generation imaging tests to help:

- Detect, diagnose & monitor early-stage cancer patients
- Detect, diagnose & monitor early-stage NASH patients

iBiopsy® Platform: Look Beyond What You See

Designing the most advanced AI/ML tech-based SaMD to enhance diagnostic performance & support clinicians to achieve the most accurate diagnosis at the earliest disease onset

The iBiopsy® CADe/CADx SaMD leverages Median's expertise and capabilities in:

- Medical device & Pharma
- Signal & Image processing
- AI & data science
- Software engineering
- Clinical development
- Regulatory, Marketing, Market access

To:

- Create the next generation of **automatic AI/ML tech-based CADe/CADx SaMD portfolio**
- Achieve **unprecedented accuracy**
- Decrease **false negative & false positive** results
- **Improve patients lives**
- Reduce **unnecessary procedures** and **healthcare spending**

Our Differentiators

iBiopsy®, the unique fully automatic CADe/CADx SaMD

Clinical value

3

## CADe/CADx: Computer-aided detection & characterization

- **Completely automatic** lesion **detection** and **characterization** into benign/malignant
- **Better accuracy** for less false negative & false positive results
- **Better patient care due to early diagnosis & treatment**
- **Less healthcare spending due to unnecessary procedures**

iBiopsy®

● **Benign**
● **Malignant**

2

CADx: Computer-aided characterization

- Automatic lesion characterization into **benign/malignant**
- Higher diagnostic accuracy
- Reduction of false positive & negative results
- Reduction of unnecessary procedures (like biopsies)

● **Benign**
● **Malignant**

1

CADe: Computer-aided detection

- Automatic organ detection
- Automatic lesion detection & quantification
- Reduction of time to find a lesion
- Increased accuracy

iBiopsy® LCS Workflow
Available as Saas or On-Premise

CT Scan → **DICOM Image** → **PACS** → **DICOM Report** → **Review Station**

iBiopsy® Gateway

iBiopsy® Processing → **AI Processing** → **DICOM Report**

Workflow

- Patient is scanned
- Image is stored in PACS
- Image is transferred to the iBiopsy® processing through iBiopsy® Gateway
- iBiopsy® DICOM report is generated and sent to the PACS through the iBiopsy® Gateway
- No user interaction, full automation.

How Big Is the Market Opportunity, Market Segments

U.S. ANNUAL TOTAL ADDRESSABLE MARKET (TAM): $30-$130B

Early Cancer Detection/Screening	High Risk Detection/Screening	Cancer Recurrence Monitoring and MDR
~$5-50B	~$2-5B depending on the indication	~$20-75B
Key Assumptions • 107MM individuals aged 50-79 • $100-500/test • Annual or biennial testing • Age expansion would increase TAM	**Key Assumptions** • Examples include monitoring tools for smokers, liver disease, and esophageal cancer • TAM is highly dependent on number of cancers included	**Key Assumptions** • ~1.8MM new cancer dx/year • Assuming use in new survivors, total survival penetration could be ~50% in 5 years • ASP: ~$1-3K/ test at varied intervals
Major Cancer Indications Lung, Breast, Colorectal, Liver, Ovarian, Esophagus, Pancreas and many others	**Major Cancer Indications** Lung, Liver, esophageal, hereditary	**Major Cancer Indications** Colorectal, Blood-based, Breast, Lung

Source: Cowen report, 2020

Lung Cancer Screening

I-ELCAP study showed a 92% survival rate at 15 years when diagnosed at stage 1 vs. 5% for stage 4 [1] - Lack of diagnosis accuracy is a major hurdle to screening adherence & programs implementation

Facts & Figures

- 1st cancer killer worldwide - 18% of all cancer deaths in 2020, equals to colorectal & liver cancers combined [2]
- 1.8M deaths in 2020, 2.4M projected in 2030 [2]
- 5-year overall survival rate 18%, 5% for distant tumors [3]
- <25% cases diagnosed in stage 1 when 5-y survival rate is between 68%-92% [4]
- >40% cases diagnosed in stage 4 when 5-y survival rate is <10% [4]
- Rising frequency among never-smokers, 20% in the US & UK [4]
- Only 870K screenings performed in the US in 2021 – 6% compliance [5]

|	LCS Programs	Target population
US	Implemented - USPSTF guidelines	14.5M (USPSTF)
Europe	- Under discussion at EU level - Implemented in Croatia - Developing in IT - Pilots in FR & UK	EU T5: 22M (Estimate)
Asia	Implemented in South Korea - Developing in China (CNCLSG guidelines), Japan (JSCTS)	ASIA T3: 102M (Estimate)

Our medical device: iBiopsy® LCS

✓ The only AI/ML technology-based end-to-end CADe/CADx SaMD indicated for early diagnosis in a high-risk population including but not limited to patients eligible for LCS programs

✓ Allows early detection, localization, characterization into benign/malignant & volumetric longitudinal tracking of lung nodules

✓ Unprecedent sensitivity & specificity performance that allows to identify tumor onset at the earliest stage versus Standard-of-Care

iBiopsy® Lung Cancer Screening (LCS)

Automatic lung nodule characterization on Stage 1 lung cancer - unprecedented lung cancer characterization performance, beyond the state-of-the-art

Test AUC = 0.984

- **Operating point** A : **Sensitivity 93.1% at Specificity 96.2%**

iBiopsy® LCS: Setting the Bar in Lung Cancer Screening

Automatic lung nodule detection & characterization on all lung cancer stages - our first results confirm our unrivalled accuracy in detecting & characterizing nodules

- **Automatic Nodule detection and Characterization**
  - Cohort: 1,760 NLST patients (16,789 Nodules)
  - Test set:
    - › 4,681 nodules (151 malignant, 4,531 benign)
    - › 471 patients (146 malignant, 325 benign)

- **Model: Combination of Deep Neural Networks, 3D-Morphological and Radiomics features**

- **Lesion Level Performance**
  - **AUC = 0.976**
  - Max Youden index
    - **Sensitivity = 94.7 %**
    - **Specificity = 93.3 %**

Receiver Operating Characteristic Test(xgboost_lesion_2D_3D_best_features test2)

Receiver Operating Characteristic

AUC = 0.98

iBiopsy® LCS Value Proposition

The only fully automatic AI tech-based CADe/CADx SaMD:
- Currently, only CADe or CADx SaMD available in the market
- Not all SaMD are completely automatic, need for radiologist intervention

Unprecedent Accuracy (sensitivity & specificity) vs:
- Radiologist alone
- All other CADe & CADx SaMD
- Liquid Biopsy

100% designed on market needs:
- Median's expertise with on-premise or cloud deployment
- Multidisciplinary global market research

Clinical validation of the highest standard:
- Standalone trial
- Multi-reader Multi-cases trial

360° Customer's support:
- Trainings, hotline 24/7, applications & engineers to enhance customer's experience

iBiopsy® LCS Value Proposition

Unprecedent Accuracy vs other CADe & CADx

COMPANY	PRODUCT	TEST TYPE	SENSITIVITY	SPECIFICITY	FP/SCAN
MEDIAN TECHNOLOGIES	**iBiopsy®**	**AI CADe**	**94.9%**	**N/A**	**1**
RIVERAIN TECH	CLEAR READT CT	AI CADe	83%	N/A	0.75
INFERVISION	INFERREAD CT LUNG	AI CADe	Not Found	N/A	Not Found
CORELINE SOFT	AVIEW LCS	AI CADe	93%	N/A	1
VITAL – CANON	VISIA CT (MeVis)	AI CADe	75%	N/A	1
ARTERYS	LUNG AI	AI CADe	93%	N/A	1.53
AIDENCE	VEYE LUNG NODULES	AI CADe	88%	N/A	1.04
VUNO	MED-LUNGCT AI	AI CADe	92.8%	N/A	1
MEDIAN TECHNOLOGIES	**iBiopsy®**	**AI CADx**	**95.3%**	**96.2%**	**N/A**
OPTELLUM	VIRTUAL NODULE CLINIC	AI CADx	99%	28%	N/A
MEDIAN TECHNOLOGIES	**iBiopsy®**	**AI CADe/CADx**	**94.7%**	**93.3%**	**N/A**

Sensitivity: the ability to correctly generate positive results for cancer patients
Specificity: the ability to correctly generate negative results for non cancer patients
Source: https://www.healthnewsreview.org/toolkit/tips-for-understanding-studies/understanding-medical-tests-sensitivity-specificity-and-positive-predictive-value/

iBiopsy® LCS Value Proposition

Unprecedent Accuracy vs Liquid Biopsy

COMPANY	PRODUCT	TEST TYPE	SENSITIVITY	SPECIFICITY
GRAIL	GALLERI	LIQUID BIOPSY LUNG – **Early Detection**	59% **stage I 18%; stage II 43%;** stage III 81%; stage IV 93%	99%
GUARDANT HEALTH	360 CDX	LIQUID BIOPSY **CGP***	63%	96%
EXACT SCIENCE	CANCERSEEK	LIQUID BIOPSY LUNG – **Early Detection**	27%	99%

Sensitivity: the ability to correctly generate positive results for cancer patients
Specificity: the ability to correctly generate negative results for non cancer patients
Source: https://www.healthnewsreview.org/toolkit/tips-for-understanding-studies/understanding-medical-tests-sensitivity-specificity-and-positive-predictive-value/

Very Early HCC Detection/Diagnosis & Recurrence

A randomized control trial showed that biannual screening reduces mortality by 37% after 5 years [1]- Current imaging diagnostics offer poor sensitivity thus limit HCC surveillance program effectiveness

Facts & Figures

- HCC accounts for 90% of all primary liver cancers [2]
- 3rd cause of cancer mortality worldwide, accounting for 8% of all cancer deaths in 2020 [3]
- 830K deaths in 2020, 1.1M projected in 2030 [3]
- 5-year survival rate 10-20%, 3% for distant tumors [4]
- Risk factors: HBV, HCV, heavy alcohol use, cirrhosis, NAFLD, obesity, T2DM
- Surveillance rates range from 10 to 40% [5]

	HCC Surveillance Programs	Target population
US	AASLD guidelines for cirrhotic patients & other high-risk patients	US: 2.3M (Estimate)
Europe	EASL guidelines for cirrhotic & other high-risk patients	EU T5: 7.4M (Estimate)
Asia	APASL guidelines for cirrhotic & & other high-risk patients	ASIA T3: 48.4M (Estimate)

Our target candidate: iBiopsy® HCC

✓ The only AI/ML technology-based end-to-end CADe/CADx SaMD indicated for surveillance of cirrhotic & other patients at high risk of HCC

✓ Allows early detection, localization, characterization into benign/malignant of liver nodules

✓ Unprecedent sensitivity & specificity performance based on iBiopsy® LCS know how – allowing tumor onset identification at the earliest stage versus Standard-of-Care

NAFLD/NASH Detection/Diagnosis

Preventing NAFLD to progress to NASH is possible if detected & managed at an early stage
Urgent need for non-invasive & cost-effective biomarkers to facilitate widespread surveillance

Facts & Figures

- NAFLD prevalence 25% worldwide [1], affecting both adults & children – 55.5% prevalence among T2DM population
- NASH prevalence 1.5%-6.5% worlwide [1]
- NASH prevalence expected to grow by 63% between 2015 & 2030 [1]
- NAFLD may become a leading contributor to cirrhosis, HCC, liver transplantation & mortality [2]
- Risk factors: Obesity, T2DM, hypertriglyceridemia, metabolic syndrome

Our target candidate: iBiopsy® NAFLD/NASH

- ✓ The only AI/ML technology-based end-to-end CADe/CADx SaMD indicated to early identify and score fibrosis in NAFLD patients

- ✓ Unprecedent sensitivity & specificity performance based on iBiopsy LCS® know how – allowing fibrosis identification when still reversible

	NAFLD Fibrosis Screening Programs	Target population
US	AASLD guidelines for high-risk patients / No systematic screening	US: 83M (Estimate)
Europe	EASL guidelines for high-risk patients / No systematic screening	EU T5: 81M (Estimate)
Asia	APASL guidelines for high-risk patients / No systematic screening	ASIA T3: 405M (Estimate)

iBiopsy® Lung & Liver SaMD suites - roadmap

	2021		2022		2023		2024		2025	
	1rst Half	2nd Half	1rst Half	2nd Half	1rst Half	2nd Half	1rst Half	2nd Half	1rst Half	2nd Half
Lung Cancer Screening	CADe/CADx Development →		FDA Q-Sub #1 (CP); FDA 513(g); FDA Q-Sub #2 (BDD); Clinical trials protocols definition		FDA Q-Sub #3 (CP); Pivotal Clinical Trials execution	FDA Q-Sub #4 (BDD)	**FDA Approval**; Regulatory filling & review	**CE Mark**		
Lung Cancer IDPN					Data acquisition & annotation campaigns; CADe/CADx Development; FDA 513(g); Clinical trials protocols definition	FDA Q-Sub (CP + BDD)	Pivotal Clinical Trials execution	Regulatory filling & review	**FDA Approval**; **2025+** **CE Mark**	
Very Early HCC De/Dx & Recurrence	CADe/CADx Development →		FDA 513(g)	FDA Q-Sub; Clinical trials protocols definition		Pivotal Clinical Trials execution	Regulatory filling & review	**FDA Approval**	**CE Mark**	
NAFLD/NASH De/Dx			CADe/CADx Development →				FDA 513(g); Clinical trials protocols definition	FDA Q-Sub; Pivotal Clinical Trials execution	Regulatory filling & review	**2025+** **FDA Approval**

FDA Q-Sub CP : Clinical Protocols, BDD : Breakthrough Device Designation.

Clinical Validation Plan: A Two Study Approach

Objective: meet the regulatory requirements (USA, EU, etc.) for End-to-End CADe/CADx

Standalone Performance Study

- **2-6 Centers, ≥312 cancer, ≥571 benign**
- **Objectives:**
  - › Assess software's standalone performance in characterizing positive and negative patients.
  - › Assess system's standalone performance in detecting and characterizing nodules

Cohort: 2-6 Centers in EU and US
≥312 cancer, ≥571 benign

Reference Standard Generation
- › Radiologist Identified lesion: location, segmentation, malignancy score

iBiopsy® Software Image Analysis
- › Automated analysis via AI based CADe/x
- › Detection, localization, and malignancy score

Statistical Analysis / Report Generation
- › Compared AI output to the Radiologist Reference Standard.

"How good is iBiopsy®"

Multi-Reader Multi-Case Study

- **360 total Patients, 4-6 Centers: 120 Cancer, 240 Benign**
- **16 Readers analyze each case with and without iBiopsy® Software**
- **Objectives:**
  - › Demonstrate iBiopsy® improves clinician performance in analyzing LDCT lung screening scans, reducing FPs and unneeded follow-up procedures

360 Patients, 16 Readers

Control Arm

Intended User + Viewer

Test Arm

Intended User + Viewer + iBiopsy®

Calculate Endpoints

"How much better is the clinician with iBiopsy®"

iCRO Business

Solutions and Services for Image Management
in Clinical Trials

iCRO Landscape and Differentiators

Landscape

- The global contract research organization (CRO) services market size was valued at USD 38bn in 2018 and is projected to reach USD 91bn by 2026

- The imaging CRO market size was valued at USD 1.3bn in 2020. The largest market segment is for oncology.

- On April 28, 2021, ERT and Bioclinica closed their merger in a $7.8bn deal -> Clario

Competitive positioning and differentiators

- Median is the only oncology-focused imaging CRO with a global footprint and partners with global CROs

- Strong technology differentiators with our proprietary platform, iSee® and evolutions

- Unique AI competitive advantages

Competitive imaging CRO landscape:

Fragmented with 3 major players

Imaging CRO Solutions and Services

Bringing more meaning to image data: iSee®

Identify

Quantify

Track

- Image analysis and data management platform

- Extracts more data from an image than any other system

- Delivers the highest quality data for better informed decisions

- Limit variability and increases reproducibility by automatically identifying, quantifying, and tracking lesions across all time points

- All readers use this advanced proprietary tool, accessed through a web-browser

- Based on a 510K FDA cleared platform

Imaging CRO Solutions and Services

Bringing more meaning to image data: iSee®

iCRO

Imaging Services for Clinical Trials

- Independent Central Review
- Collect & Hold

Additional Insights

Imaging Lab
- AI
- Data Mining
- Radiomics

Major partnership with a pharmaceutical company

Step by step approach, developing a biomarker attached to a drug

iBiopsy®

Patient Care

- Early Diagnosis
- Disease Monitoring

Imaging Lab Internal capabilities

- Academic partners
- Industrial partners

Median's AI Competitive Advantage

Provide additional insights for clinical trials

1| Better selection of patients

2| Prediction of response to therapy

3| Accurate monitoring for disease progression

4| Safety assessment

Ex. 1: Better uderstanding of the MoA (1/2)

Example of work done on molecular features

➡️ **iBiopsy® CD8+ in NSCLC**

Journal of Clinical Oncology®
An American Society of Clinical Oncology Journal

Journal of Clinical Oncology > List of Issues > Volume 39, Issue 15 suppl >

Meeting Abstract | 2021 ASCO Annual Meeting I

LUNG CANCER—NON-SMALL CELL METASTATIC

Machine learning based biomarkers to predict CD8 infiltration in non-small cell lung cancers using CT imaging.

Check for updates

Yan Liu, Danny Francis, Vladimir Groza, Charles Voyton, Afef Baili-Laya, Benoit Huet, ...

Methods: To study CD8 infiltration we extracted patients that included CT scans and CD8 transcript data from publicly available cohorts (TCGA-LUSC, TCGA-LUAD, NSCLC-Radiogenomics) to produce the Lung3 cohort (104 patients). Using this cohort, we trained (80 patients) and tested (24 patients) an AI model to predict tumor CD8 infiltration using patient CT scans as the sole input. CD8 expression (high and low) was characterized using transcriptomic quantification and served as surrogate for CD8+ infiltration, following previously described methods. Supervised and unsupervised models previously trained to identify lung features were trained to identify CD8 status using the CD8 expression data provided in the Lung3 dataset. Algorithm performance was tested on a randomly chosen subset of the cohort (24 patients) and compared against transcriptomic confirmed CD8 expression. AUC were calculated for supervised and unsupervised models. **Results:** AUC for the supervised and unsupervised models generated using the Lung3 cohort are shown below. Our results suggest that the derived supervised and unsupervised models could identify the CD8 infiltration status using only patient CT scans in the test dataset. **Conclusions:** The machine learning based models described here show encouraging results suggesting that CT imaging of NSCLC lung cancers contain sufficient information to predict the CD8 infiltration status of tumors. Although these results are just a proof of concept, the promise of a CT based non-invasive marker for tumor immune status is encouraging to help advance treatment efficacy in the ever-growing field of ICI therapy. References: (1)Wu, X. *et al.* (2019). (2) Schulze, A. B. *et al.* (2020). (3) Sun, R. *et al.* (2018).

	Supervised Model	Unsupervised Model
One-layer Neural Network	0.721	0.657
K nearest neighbors (K =1000)	0.700	0.750

Ex. 2: Real life data and data mining

Retrospective: Need to explain why a study has failed

Prospective : Need to improve design of future studies

➡ Deep Imaging Analysis of the Study Population using existing databases

- **Side Analysis** of the central independent reading performed for efficacy or eligibility assessment
  - No mandatory reread & cost saving for all imaging biomarker
- **Baseline is sufficient** for most of the analysis
  - Ongoing initial analysis
  - No mandatory imaging needed after baseline (cost saving)
- **Understanding of non-responder/responder** patients
  - Predictive / Prognostic Imaging Biomarker
- **Deep analytics** at the population level centered on 2 Regions Of Interests :
  - Tumor Typology
  - Host (patient) Health Status
- **Automatic or Semi-Automated** Analysis pipeline

Experience by Phase

As of September 30, 2022

213 Trials*

31	Phase I trials
30	Phase I/II trials
76	Phase II trials
5	Phase II/III trials
71	Phase III trials

- [*] Cumulative contracted and less than 12-month awarded studies, since the beginning of the iCRO activity, and until September 30, 2022

- **10 supported regulatory approvals**
- 2,500+ hospitals (investigator sites)
- + 40% of trials is for immuno-oncology
- 60+ clients in the US and in Europe
- 20+ clients in China
- 3 successful FDA inspections (2017, 2019 and 2021)
- 8 successful NMPA inspections (3 in 2022)
- 23,750 patients enrolled
- QCd scanners: 110,000

www.mediantechnologies.com | October 2022

iCRO Business Development Accelerator

Median Technologies confirmed as a preferred vendor by one of the Top 3 pharmaceutical companies in the world

- Renegotiation of terms of an existing Master Service Agreement (MSA) with this major big pharmaceutical company.

- The new scope of the MSA covers Phase III clinical trials for major indications in oncology and the terms are valid for 3 years.

- This partnership will contribute to sustain Median's future bookings and revenues growth.

iCRO Growth Opportunities

# of RFP received

Legend: Asia, EU, US
Years: 2018, 2019, 2020, 2021

Order backlog evolution

Legend: €m
Years: 2018, 2019, 2020, 2021

iCRO Business Development Triggers

1 Access to RFPs

2 Win rate

3 Phase III #

4 AI offering

Tactics

- Develop partnerships with global CROs
- Increase repeat business with Top Pharmas
- Target Top 200 biotech companies

2022 and Beyond

iBiopsy®

- iBiopsy®LCS pivotal study initiation in 2022

- iBiopsy® LCS Expected FDA approval Q1 2024

- iBiopsy® HCC and iBiopsy® NASH validation studies in 2022/2023

iCRO

- Major potential for growth in a very dynamic market

- Very strong AI technology differentiators for clinical trials

Our Core Values

Leading innovation with purpose
Combine the spirit of innovation with our passion and conviction to help cure cancer and other debilitating diseases.

Committing to quality in all we do
Be dedicated to quality in everything we do. Quality begins with us and we are committed to it.

Supporting our customers in achieving their goals
Listen to the needs of our customers and help make their goals our goals through our innovation, imaging expertise, superior services, and quality solutions.

Putting the patient first
There is a person at the other end of the images we analyze who is counting on us to do everything we can to help make them healthier.

ALMDT
EURONEXT
GROWTH

European **Rising** Tech
LABEL

www.mediantechnologies.com

Sources

LCS (slide 13):

(1) https://www.redjournal.org/article/S0360-3016(19)30110-5/fulltext
(2) https://gco.iarc.fr/
(3) https://www.lung.org/lung-health-diseases/lung-disease-lookup/lung-cancer/resource-library
(4) https://www.lungambitionalliance.com/our-initiatives/lung-cancer-screening-the-cost-of-inaction.html
(5) https://nrdrsupport.acr.org/support/solutions/articles/11000093991-lcsr-state-reports

HCC (slide 19):
(1) https://pubmed.ncbi.nlm.nih.gov/15042359/
(2) https://www.nature.com/articles/s41572-020-00240-3
(3) https://gco.iarc.fr/
(4) https://www.ajmc.com/view/humanistic-and-economic-burden-of-hepatocellular-carcinoma-systematic-literature-review
(5) https://pubmed.ncbi.nlm.nih.gov/27531119/

NAFLD/NASH (slide 20):
(1) https://www.the-nash-education-program.com/
(2) https://pubmed.ncbi.nlm.nih.gov/31574071/#:~:text=Nonalcoholic%20fatty%20liver%20disease%20is%20known%20as%20a%20silent%20disease,%2C%20liver%20transplantation%2C%20and%20mortality
(3) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366581/